The AHA yesterday voiced support for the Opioid Treatment Access Act (H.R. 6279), bipartisan legislation that would take steps to facilitate patients’ access to methadone treatment for opioid use disorder. The bill would direct the Substance Abuse and Mental Health Services Administration to study the impact of certain flexibilities implemented during the COVID-19 public health emergency to enhance access to methadone treatment services and reduce stigma; allow patients to receive one-month supplies of methadone after two years of continuous treatment; permit pharmacies to dispense methadone; and codify regulations that allow opioid treatment programs to operate mobile medication components without separate registration.

Related News Articles

#HealthCareInnovation Thursday Blog
How could I have been so unprepared? I held my 3-year-old’s hand tighter than a pediatrician would approve of as together we watched paramedics resuscitate…
Headline
The Food and Drug Administration seeks comments through June 21 on a potential change that would require outpatient settings to dispense opioid pain…
Headline
AHA yesterday voiced support for H. Res. 909, which condemns violence against health care workers and expresses support for health care personnel. “The…
Headline
The Substance Abuse and Mental Health Services Administration today announced $25.6 million in grants to expand access to medication-assisted treatment…
Headline
Without additional funding from Congress, the U.S. cannot secure sufficient COVID-19 vaccine boosters and variant-specific vaccines for all Americans;…
Headline
The Senate Health, Education, Labor & Pensions committee today voted 20-2 to advance, as amended, the PREVENT Pandemics Act (S. 3799), bipartisan…